Tirzepatide (10 mg)

Tirzepatide (10 mg) — Research Overview

Tirzepatide is a dual-receptor agonist studied across metabolic and weight-loss peptide research in Canada. It was the first dual-agonist of its kind, acting on both GLP-1 and GIP receptor systems.

Mechanism & Research Applications

Tirzepatide is researched for simultaneous activation of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors — a combination studied for greater metabolic effect than GLP-1 alone. Clinical trials recorded substantial weight reductions, and research now spans metabolic, hepatic, and cardiovascular models.

As the established dual-agonist benchmark, tirzepatide sits between single-receptor semaglutide and triple-receptor retatrutide in the metabolic research landscape.

Specifications

10 mg lyophilized powder per vial | ≥99% purity (HPLC-verified) | Batch-specific COA included

Quality & Sourcing in Canada

NuMe supplies Tirzepatide (10 mg) as part of its catalogue of weight loss peptides in Canada, research peptides in Canada, and buy peptides in Canada. Every batch is verified to ≥99% purity by HPLC, ships domestically from within Canada (typically 1–3 business days), and includes a batch-specific Certificate of Analysis. Free shipping applies to orders over $300 CAD.

Frequently Asked Questions

For Research Purposes Only. This product is intended exclusively for laboratory research and in-vitro testing. It is not for human or veterinary use, consumption, or any therapeutic application.